CLINICAL TRIALS PROFILE FOR CROTAMITON

All Clinical Trials for crotamiton

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Tishreen University Hospital	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	University of Aleppo	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.
NCT06396507 ↗	Sulfur vs. Different Regimes of Permethrin for Scabies	COMPLETED	Damascus University	PHASE3	2022-03-15	In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, the investigators are comparing four different regimens of permethrin application and comparing Sulfur to permethrin in terms of efficacy and safety.

Clinical Trial Conditions for crotamiton

Condition Name

Condition Name for crotamiton
Intervention	Trials
Scabies	2

Condition MeSH

Condition MeSH for crotamiton
Intervention	Trials
Scabies	2
Skin Diseases, Infectious	1
Skin Diseases	1

Clinical Trial Locations for crotamiton

Trials by Country

Trials by Country for crotamiton
Location	Trials
Pakistan	1
Syria	1

Clinical Trial Progress for crotamiton

Clinical Trial Phase

Clinical Trial Phase for crotamiton
Clinical Trial Phase	Trials
PHASE3	1
EARLY_PHASE1	1

Clinical Trial Status

Clinical Trial Status for crotamiton
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	1
COMPLETED	1

Clinical Trial Sponsors for crotamiton

Sponsor Name

Sponsor Name for crotamiton
Sponsor	Trials
Tishreen University Hospital	1
University of Aleppo	1
Damascus University	1

Sponsor Type

Sponsor Type for crotamiton
Sponsor	Trials
OTHER	4

Last updated: May 2, 2026

Crotamiton: Clinical Trials Update, Market Analysis, and Projection

Crotamiton is an anti-scabietic/anti-pruritic topical drug with a long marketed history, mainly in the treatment of scabies and pruritus. Public, regulator-grade “clinical trials update” data is limited to older filings and routine post-marketing use; current development activity is not supported by a consistent recent clinical-trial footprint in major global registries based on publicly indexed records available through this interface.

What is crotamiton’s current clinical development footprint?

Are there active or recently completed clinical trials (global registries) for crotamiton?

No complete, up-to-date, regulator-verifiable set of active or recently completed clinical studies for crotamiton can be produced from the information available in this interface.

What is the practical clinical implication of that data gap?

• The commercial lifecycle for crotamiton appears driven primarily by established labeling, generics, and topical OTC or prescription channel dynamics rather than by new pivotal clinical evidence.
• Any “trial update” produced without an auditable list of NCT/CTRI/EudraCT/ISRCTN identifiers and outcomes would not meet decision-grade standards for investors or R&D planning, so no trial table is provided here.

What is the market structure for crotamiton?

Where does crotamiton sit in the topical anti-scabietics landscape?

Crotamiton competes in the topical scabicide class alongside permethrin and sulfur-based regimens, with commercial positioning shaped by:

• Formulation type (cream vs lotion)
• Intended use (scabies vs pruritus)
• Regulatory pathway (brand vs generic; prescription vs non-prescription depending on country)
• Safety and tolerability profile in sensitive populations (children, pregnancy considerations vary by jurisdiction)

What is the likely commercial basis (brand vs generic)?

Based on its marketed maturity and typical industry structure for older topical actives, the market is predominantly:

• Generic-led across many geographies
• Discount-price competitive at the product level (same active, different excipients and packaging)
• Influenced by formulary access and reimbursement rules where prescription-only

Market segmentation (decision-useful cut)

Segment	Typical buyer/channel	Value driver
Scabies treatment	Retail pharmacy, primary care	Formulary access, price, availability
Pruritus relief	Retail OTC/prescription (jurisdiction-dependent)	Speed of symptom relief claims, tolerability, brand trust
Pediatric-sensitive use	Retail and prescriber channels	Label age guidance, safety perceptions

Market analysis: what moves revenue for crotamiton?

Key demand drivers

1. Scabies incidence cycles and outbreaks: Local surges create periodic demand spikes, but the product category often returns to baseline quickly.
2. Switching between scabicides: Permethrin and alternatives often hold prescribing mindshare where first-line protocols are in place. Crotamiton’s share depends on guideline acceptance, payer preference, and product availability.
3. Channel packaging and dosing convenience: Tubes vs bottles, patient-friendly instructions, and travel-friendly formats influence repeat purchase and adherence.
4. Safety and tolerability perceptions: Topical irritancy profiles affect re-purchase and clinician comfort.

Key supply and pricing drivers

• Generic competition compresses unit prices and makes growth more dependent on volume and channel penetration.
• Manufacturing continuity (formulation know-how, stability, and quality systems) often matters more than differentiation once generics proliferate.

How should investors and R&D teams project market performance?

Projection approach

A credible projection requires quantifiable baseline sales by geography, plus formulary and competitive share. Those numeric baselines are not available in this interface in an auditable form, so a decision-grade numeric forecast cannot be produced without fabricated data.

Actionable direction without unsupported numbers

Project performance using scenario logic tied to observable levers:

• Base case: stable demand from routine scabies/pruritus cycles; modest growth from distribution expansion in underpenetrated regions.
• Downside: further share erosion where permethrin or sulfur regimens dominate first-line guidance; continued price compression as more generics enter.
• Upside: formulary reinstatement or guideline inclusion in a region plus channel expansion through pharmacy chains; differentiation through better tolerability formulations (though that would require demonstrable regulatory/clinical support).

Where does differentiation likely come from for crotamiton?

Product development paths that can move share

Because crotamiton is mature, incremental product development usually targets:

• Formulation improvements: reduced irritancy, better spreadability, faster absorption feel
• Packaging and dosing: compliance improvements
• Clinical positioning: targeting segments where current competitors underperform (age-specific comfort, symptom-relief claims backed by study data)

Regulatory positioning

For an established topical active, differentiation typically relies on:

• Bioequivalence or comparability work (depending on jurisdiction and whether a new formulation is treated as the same drug)
• Label expansion support through additional studies or bridging datasets
• Pharmacovigilance strength and safety narratives supported by existing post-marketing experience

What should be tracked to update projections?

Operational KPIs (non-numeric, decision-grade)

• New approvals or label changes (age indications, scabies vs pruritus scope)
• Generic launches by major manufacturers in key markets
• Changes in guideline recommendations for scabies first-line therapy in target jurisdictions
• Distribution wins or loss with chain pharmacies and institutional formularies

Key Takeaways

• Crotamiton’s clinical development is not supported here by a verifiable, current global trial list; a factual “clinical trials update” table cannot be produced without registry identifiers and outcomes.
• The market is structurally generic-led and price-competitive, with demand driven by scabies incidence cycles and jurisdiction-specific reimbursement and OTC/prescription channel rules.
• Numeric market projections cannot be produced in a decision-grade way from this interface without auditable baseline sales and competitive share data.
• Market upside is most plausibly driven by channel/formulary gains and formulation differentiation backed by regulatory evidence; downside risk comes from continued switching to dominant first-line regimens and further price compression.

FAQs

1. Is crotamiton currently in active late-stage clinical development?
   No evidence sufficient for a decision-grade determination is available in this interface.

2. What conditions does crotamiton treat commercially?
   Scabies treatment and pruritus relief, with exact labeling depending on jurisdiction.

3. How do generics affect crotamiton pricing?
   Generic entry typically compresses unit prices and shifts growth toward volume and distribution gains.

4. What competitor products most directly pressure crotamiton share?
   Other topical scabicides such as permethrin and sulfur-based regimens, depending on local guideline and formulary preferences.

5. What is the most realistic growth lever for a mature topical active like crotamiton?
   Channel penetration and formulation or tolerability differentiation that supports label-consistent market positioning.

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. (crotamiton search results). https://clinicaltrials.gov/
[2] European Medicines Agency. (crotamiton-related assessments). https://www.ema.europa.eu/
[3] WHO Model List of Essential Medicines. (topical scabicides context). https://www.who.int/medicines/publications/essential-medicines/en/